Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
2.100
+0.020 (0.96%)
At close: May 12, 2025, 4:00 PM
2.060
-0.040 (-1.90%)
After-hours: May 12, 2025, 6:04 PM EDT
Artiva Biotherapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Artiva Biotherapeutics stock have an average target of 20, with a low estimate of 18 and a high estimate of 23. The average target predicts an increase of 852.38% from the current stock price of 2.10.
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 8, 2025.
Analyst Ratings
The average analyst rating for Artiva Biotherapeutics stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +995.24% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +852.38% | Mar 26, 2025 |
| Wedbush | Wedbush | Buy Reiterates $18 | Buy | Reiterates | $18 | +757.14% | Mar 25, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $23 → $20 | Buy | Maintains | $23 → $20 | +852.38% | Mar 25, 2025 |
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +995.24% | Mar 25, 2025 |
Financial Forecast
Revenue This Year
n/a
from 251.00K
Revenue Next Year
n/a
EPS This Year
-2.99
from -5.81
EPS Next Year
-2.90
from -2.99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | n/a |
| Avg | n/a | n/a | n/a |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.74 | -2.24 | -1.79 |
| Avg | -2.99 | -2.90 | -2.91 |
| Low | -3.33 | -3.37 | -4.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.